Hoofddorp, the Netherlands, 12 February 2020. IGEA Pharma N.V. (SIX: IGPH) today announced its intention to acquire a majority stake in Medical Jet Srl (“Medical Jet”), a privately held company operating in the pathogen’s decontamination of air and inanimate environmental surfaces and in air
sterilization and purification. A memorandum of understanding has been signed and subject to the satisfaction of certain customary conditions for a transaction of this type, IGEA expect to close the acquisition by June 2020. Further details of the transaction were not disclosed at this stage.
Press releases/News
The international healthcare group Acalis intends to distribute IGEA’s tests kits and dietary supplements along with Meditalia’s polymeric based med-tech products.
Continue reading →Hoofddorp, the Netherlands, 8 January 2020. IGEA Pharma N.V. (SIX: IGPH) today announced that the extraordinary general meeting followed all recommendations of the company. The minutes of the extraordinary general meeting is available at igeapharma.nl/category/information-for-shareholders
Continue reading →This press release complements today’s announcement “IGEA calls extraordinary general meeting” to be viewed here.
Hoofddorp, the Netherlands, 3 December 2019. IGEA Pharma N.V. (SIX: IGPH) today announced changes in its supervisory board. As announced today by separate press release, IGEA proposes to its shareholders to amend the articles of association by introducing a one-tier board structure with executive and non-executive directors. The current supervisory board will be abolished as a corporate body in connection with this proposed amendment. Giovanni Ferrario and Mark de Simone, chairman and member, respectively, of the current supervisory board, will stand for election as non-executive directors. Federico Bazzoni and Flavio Peralda resigned and will no longer serve as directors.
Continue reading →FOR RELEASE IN SWITZERLAND – THIS IS A RESTRICTED COMMUNICATION AND YOU MUST NOT FORWARD IT OR ITS CONTENTS TO ANY PERSON TO WHOM FORWARDING THIS COMMUNICATION IS PROHIBITED. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN.
Hoofddorp, the Netherlands, 3 December 2019. IGEA Pharma N.V. (SIX: IGPH) today announced the convening of an extraordinary general meeting (the “EGM”) for Wednesday, 8 January 2020. The EGM will resolve on the acquisition of the spin-off of Meditalia S.r.l. and on the proposal to authorize the management board to issue new shares (with respect to the acquisition of Meditalia, see also IGEA’s press release of 20 November 2019). IGEA plans to raise approximatively EUR 5 million gross proceeds through a capital increase in order to finance the further commercialization of its product portfolio which will include also the med-tech products of the planned spin-off of Meditalia S.r.l. IGEA expects to carry out its fundraising between March and April 2020. As previously announced, up to EUR 1 million new funds are committed by certain of the current shareholders of Meditalia S.r.l.
Continue reading →FOR RELEASE IN SWITZERLAND – THIS IS A RESTRICTED COMMUNICATION AND YOU MUST NOT FORWARD IT OR ITS CONTENTS TO ANY PERSON TO WHOM FORWARDING THIS COMMUNICATION IS PROHIBITED. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN.
Hoofddorp, The Netherlands, 20 November 2019. IGEA Pharma N.V. (the “Company” and together with its subsidiaries “IGEA” or the “Group”) today announced the entry into a transaction agreement (the “Agreement”) to acquire the spinoff of the med-tech activities of privately held Meditalia S.r.l. concerning the distribution in Europe of polymeric based products and devices for medical use (the “Spin-off”). Subject to the satisfaction of certain closing conditions as detailed below, it is currently expected that the acquisition will close by March 2020.
Following the acquisition, IGEA will have a broad commercial-stage portfolio of health-tech and med-tech products with presence on both the US and the EU and potential cross market opportunities. Key elements of the acquisition strategy include (i) establish solid products market positions; (ii) capitalize on operational synergies and management experience to achieve profitability; and (iii) strengthen the overall financial position of IGEA.
Continue reading →Hoofddorp, The Netherlands, 2 October 2019. IGEA Pharma N.V. (the “Company” and together with its subsidiaries “IGEA” or the “Group”) today announced that the collaboration with Diego Mortillaro is terminated. The former CEO resigned due to personal reasons. Diego Mortillaro remains one of the major shareholders of the Company with a look-up engagement until December 2019.
Continue reading →Hoofddorp, The Netherlands, 15 August 2019. IGEA Pharma N.V. (the “Company” and together with its subsidiaries “IGEA” or the “Group”) today announced the disclosure of its half-2019 financials.
Continue reading →Hoofddorp, the Netherlands, 14 July 2019. IGEA Pharma N.V. (the “Company” and together with its subsidiaries “IGEA” or the “Group”) today announced the launch of Alz1, the first solution designed to detect and reduce high free copper levels in the bloodstream – a risk factor associated with Alzheimer’s disease – through a first-of-its-kind in-home blood test and a dietary supplement for those with elevated free copper levels.
Continue reading →Hoofddorp, The Netherlands, 6 June 2019. IGEA Pharma N.V. (the “Company” and together with its subsidiaries “IGEA” or the “Group”) today announced that the annual general meeting followed all recommendations of the Company.
Continue reading →